DECADE results published looking at combination treatment with SGLT-2 inhibitor and GLP1 receptor agonist in type 2 diabetes patients

The results of a study evaluating treatment with a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, a glucagon-like peptide receptor agonist (GLP1-RA), and combination treatment with both agents in patients with type 2 diabetes patients was recently published in Diabetes, Obesity and Metabolism.

The Dapagliflozin, Exenatide and Combination for Albuminuria reduction in Diabetes (DECADE) study was conducted as a collaborative effort between researchers from the University of Groningen, Martini Hospital, Isala Hospital, AstraZeneca, Amsterdam UMC and Antaros Medical. It was designed to investigate whether the combination of a SGLT-2 inhibitor and a GLP1-RA was more effective in reducing albuminuria than either therapy alone.

Progressive kidney function decline is still seen in a large proportion of patients. To further our understanding of kidney disease, more information is needed regarding the mechanisms of action underlying the observed nephroprotective effects of treatment options like SGLT-2 inhibitors and GLP1-RAs.

The DECADE study included several outcomes; both physical and biochemistry measurements, as well as renal hemodynamic parameters as determined using Magnetic Resonance Imaging (MRI). You can read more about using imaging to assess cardiorenal effects in Our work.

Title: Albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes: a randomised cross-over clinical study
Authors: van der Aart-van der Beek AB, Apperloo E, Jongs N, Rouw DB, Sjöström CD, Friedli I, Johansson L, van Raalte DH, Hoogenberg K, Heerspink HJL

Find the publication here.

Share on Linkedin Share on Twitter